Jump to content

Drugs and Lactation Database, 2021 Domperidone Review


Recommended Posts

  • Moderator Emeritus





No authors listed
In: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–.
2021 Aug 16.
Free Books & Documents


Domperidone is not approved for marketing in the United States by the U.S. Food and Drug Administration (FDA), but is available in other countries. Domperidone may also be available from some compounding pharmacies in the US. The quality of such products cannot be assured, and the FDA has warned against their use.[1]


Data available from 4 small studies on the excretion of domperidone into breastmilk are somewhat inconsistent, but infants would probably receive less than 0.1% of the maternal weight-adjusted dosage. No adverse effects have been found in a limited number of published cases of breastfed infants whose mothers were taking domperidone.


Domperidone is sometimes used as a galactogogue to increase milk supply.[2] Galactogogues should never replace evaluation and counseling on modifiable factors that affect milk production.[3,4] Most mothers who are provided instruction in good breastfeeding technique and breastfeed frequently are unlikely to obtain much additional benefit from domperidone. Several meta-analyses of domperidone use as a galactogogue in mothers of preterm infants concluded that domperidone can increase milk production acutely in the range of 90 to 94 mL daily.[5-7] Other reviewers concluded that improvement of breastfeeding practices seems more effective and safer than off-label use of domperidone.[8,9]


Domperidone has no officially established dosage for increasing milk supply. Most published studies have used domperidone in a dosage of 10 mg 3 times daily for 4 to 10 days. Two small studies found no statistically significant additional increase in milk output with a dosage of 20 mg 3 times daily compared to a dosage of 10 mg 3 times and that women who failed to respond to the low dosage did not respond to the higher dosage.[10,11] Dosages greater than 30 mg daily may increase the risk of arrhythmias and sudden cardiac death in patients receiving domperidone,[12] although some feel that the risk is less in nursing mothers because of their relatively younger age.[13] Large database retrospective cohort studies in Canada found an increase in the risk of cardiac arrhythmias and sudden cardiac death, but some confounders make the results subject to question.[14,15] In one case, domperidone use uncovered congenital long QT syndrome in a woman who developed loss of consciousness, behavioral arrest, and jerking while taking domperidone.[16] Mothers with a history of cardiac arrhythmias should not receive domperidone and all mothers should be advised to stop taking domperidone and seek immediate medical attention if they experience signs or symptoms of an abnormal heart rate or rhythm while taking domperidone, including dizziness, palpitations, syncope or seizures.[12]

Maternal side effects of domperidone reported in galactogogue studies and cases reported to the FDA include dry mouth, headache, dizziness, nausea, abdominal cramping, diarrhea, palpitations malaise, and shortness of breath. Some of these were more frequent with dosages greater than with 30 mg daily.[10,11,17-19] Surveys of women taking domperidone for lactation enhancement found gastrointestinal symptoms, breast engorgement, weight gain, headache, dizziness, irritability, dry mouth and fatigue were the most common side effects reported.[20,21] Drug withdrawal symptoms consisting of insomnia, anxiety, and tachycardia were reported in a woman taking 80 mg of domperidone daily for 8 months as a galactogogue who abruptly tapered the dose over 3 days.[22] Another mother took domperidone 10 mg three times daily for 10 months as a galactagogue and stopped abruptly. After discontinuation, she experienced severe insomnia, severe anxiety, severe cognitive problems and depression.[23] A third postpartum woman began domperidone 90 mg daily, increasing to 160 mg daily to increase her milk supply. Because her milk supply did not improve, she stopped nursing at 14 weeks and began to taper the domperidone dosage by 10 mg every 3 to 4 days. Seven days after discontinuing domperidone, she began experiencing insomnia, rigors, severe psychomotor agitation, and panic attacks. She restarted the drug at 90 mg daily and tapered the dose by 10 mg daily each week. At a dose of 20 mg daily, the same symptoms recurred. She required sertraline, clonazepam and reinstitution of domperidone at 40 mg daily, slowly tapering the dose over 8 weeks. Three months were required to fully resolve her symptoms.[24] In a fourth case, a mother took domperidone 20 mg four times daily for 9 months to stimulate breastmilk production. She stopped breastfeeding and domperidone at that time. Two weeks later, she presented with insomnia, anxiety, nausea, headaches and palpitations. The drug was restarted at a dosage of 20 mg three times daily and began to taper the daily dosage by 10 mg every week, but after one week she complained of insomnia. Tapering was reduced to 5 mg every week, but whenever she stopped the drug, symptoms returned. She was able to discontinue domperidone after tapering the daily dosage by 2.5 mg weekly over 10 months.[25]

Similar articles


    1. Anon. FDA warns against women using unapproved drug, domperidone, to increase milk production. FDA Talk Paper 2004:http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm173886.htm. Accessed October 10, 2012.
    1. Winterfeld U, Meyer Y, Panchaud A, et al. Management of deficient lactation in Switzerland and Canada: A survey of midwives' current practices. Breastfeed Med. 2012;7:317–8. - PubMed
    1. Brodribb W. ABM Clinical Protocol #9 Use of galactogogues in initiating or augmenting maternal milk production, second revision 2018. Breastfeed Med. 2018;13:307–14. - PubMed
    1. Breastfeeding challenges: ACOG Committee Opinion, Number 820. Obstet Gynecol. 2021;137:e42–e53. - PubMed
    1. Grzeskowiak LE, Smithers LG, Amir LH, et al. Domperidone for increasing breast milk volume in mothers expressing breast milk for their preterm infants: A systematic review and meta-analysis. BJOG. 2018;125:1371–8. - PubMed
    1. Taylor A, Logan G, Twells L, et al. Human milk expression after domperidone treatment in postpartum women: A systematic review and meta-analysis of randomized controlled trials. J Hum Lact. 2019;35:501–9. - PubMed
    1. Shen Q, Khan KS, Du MC, et al. Efficacy and safety of domperidone and metoclopramide in breastfeeding: A systematic review and meta-analysis. Breastfeed Med. 2021;16:516–29. - PubMed
    1. Anderson PO, Valdes V. A critical review of pharmaceutical galactagogues. Breastfeed Med. 2007;2:229–42. - PubMed
    1. Paul C, Zenut M, Dorut A, et al. Use of domperidone as a galactagogue drug: A systematic review of the benefit-risk ratio. J Hum Lact. 2015;31:57–63. - PubMed
    1. Wan EW, Davey K, Page-Sharp M, et al. Dose-effect study of domperidone as a galactagogue in preterm mothers with insufficient milk supply, and its transfer into milk. Br J Clin Pharmacol. 2008;66:283–9. - PMC - PubMed
    1. Knoppert DC, Page A, Warren J, et al. The effect of two different domperidone dosages on maternal milk production. J Hum Lact. 2013;29:38–44. - PubMed
    1. Health Canada endorsed important safety information on domperidone maleate. 2012:http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2012/domperi.... Accessed October 10, .
    1. Bozzo P, Koren G, Ito S. Health Canada advisory on domperidone: Should I avoid prescribing domperidone to women to increase milk production? Can Fam Physician. 2012;58:952–3. - PMC - PubMed
    1. Smolina K, Mintzes B, Hanley GE, et al. The association between domperidone and ventricular arrhythmia in the postpartum period. Pharmacoepidemiol Drug Saf. 2016;25:1210–4. - PubMed
    1. Moriello C, Paterson JM, Reynier P, et al. Off-label postpartum use of domperidone in Canada: a multidatabase cohort study. CMAJ Open. 2021;9:E500–e9. - PMC - PubMed
    1. Blusztein D, Peters S, Joshi S. Diagnosis of long QT syndrome triggered by domperidone use for breast-feeding. Heart Lung Circul 2017;26:S163. Abstract. doi:10.1016/j.hlc.2017.06.274 - DOI
    1. Jantarasaengaram S, Sreewapa P. Effects of domperidone on augmentation of lactation following cesarean delivery at full term. Int J Gynaecol Obstet. 2012;116:240–3. - PubMed
    1. Ingram J, Taylor H, Churchill C, et al. Metoclopramide or domperidone for increasing maternal breast milk output: A randomised controlled trial. Arch Dis Child Fetal Neonatal Ed. 2012;97:F241–5. - PubMed
    1. Sewell CA, Chang CY, Chehab MM, et al. Domperidone for lactation: What health care providers need to know. Obstet Gynecol. 2017;129:1054–8. - PubMed
    1. Hale TW, Kendall-Tackett K. Clin Lact (Amarillo) 2018;9:10–7. doi: 10.1891/2158-0782.9.1.10. Cong Z. Domperidone versus metoclopramide: Self-reported side effects in a large sample of breastfeeding mothers who used these medications to increase milk production. doi. - DOI
    1. McBride GM, Stevenson R, Zizzo G, et al. Use and experiences of galactagogues while breastfeeding among Australian women. PLoS One. 2021;16:e0254049. - PMC - PubMed
    1. Papastergiou J, Abdallah M, Tran A, et al. Domperidone withdrawal in a breastfeeding woman. Can Pharm J (Ott) 2013;146:210–2. - PMC - PubMed
    1. Seeman MV. Transient psychosis in women on clomiphene, bromocriptine, domperidone and related endocrine drugs. Gynecol Endocrinol. 2015;31:751–4. - PubMed
    1. Doyle M, Grossman M. Case report: Domperidone use as a galactagogue resulting in withdrawal symptoms upon discontinuation. Arch Womens Ment Health. 2018;21:461–3. - PubMed
    1. Manzouri P, Mink M. Withdrawal effects from domperidone requiring prolonged tapering schedule. Pharmacotherapy. 2017;37:e112–Abstract 213. doi: 10.1002/phar.2028. - DOI
    1. De Leo V, Petraglia F, Sardelli S, et al. Minerva Ginecol. 1986;38:311–5. [Use of domperidone in the induction and maintenance of maternal breast feeding] - PubMed
    1. Petraglia F, De Leo V, Sardelli S, et al. Domperidone in defective and insufficient lactation. Eur J Obstet Gynecol Reprod Biol. 1985;19:281–7. - PubMed
    1. da Silva OP, Knoppert DC, Angelini MM, et al. Effect of domperidone on milk production in mothers of premature newborns: A randomized, double-blind, placebo-controlled trial. CMAJ. 2001;164:17–21. - PMC - PubMed
    1. Asztalos EV, Campbell-Yeo M, da Silva OP, et al. Enhancing human milk production with domperidone in mothers of preterm infants. J Hum Lact. 2017;33:181–7. - PubMed
    1. Madjunkov M, Chaudhry S, Fujioka I, et al. Safety of domperidone as a galactogogue: A retrospective chart review study. Birth Defects Res 2017;109 (Special Issue: SI):712. Abstract. doi:10.1002/bdr2.1061 - DOI
    1. Reisman T, Goldstein Z. Case report: Induced lactation in a transgender woman. Transgend Health. 2018;3:24–6. - PMC - PubMed
    1. Wamboldt R, Shuster S, Sidhu BS. Lactation induction in a transgender woman wanting to breastfeed: Case report. J Clin Endocrinol Metab. 2021;106:e2047–e52. - PubMed
    1. Brouwers JR, Assies J, Wiersinga WM, et al. Plasma prolactin levels after acute and subchronic oral administration of domperidone and of metoclopramide: a cross-over study in healthy volunteers. Clin Endocrinol (Oxf) 1980;12:435–40. - PubMed
    1. Hofmeyr GJ, van Iddekinge B, Blott JA. Domperidone: Secretion in breast milk and effect on puerperal prolactin levels. Br J Obstet Gynaecol. 1985;92:141–4. - PubMed
    1. Brown TE, Fernándes PA, Grant LJ, et al. Effect of parity on pituitary prolactin response to metoclopramide and domperidone: implications for the enhancement of lactation. J Soc Gynecol Investig. 2000;7:65–9. - PubMed
    1. Poovathingal MA, Bhat R. Ramamoorthi. Domperidone induced galactorrhea: An unusual presentation of a common drug. Indian J Pharmacol. 2013;45:307–8. - PMC - PubMed
    1. Jabbar A, Khan R, Farrukh SN. Hyperprolactinaemia induced by proton pump inhibitor. J Pak Med Assoc. 2010;60:689–90. - PubMed
    1. Nijhawan S, Rai RR, Sharma CM. Domperidone induced galactorrhea. Indian J Gastroenterol. 1991;10:113. - PubMed
    1. Cann PA, Read NW, Holdsworth CD. Galactorrhoea as side effect of domperidone. Br Med J (Clin Res Ed) 1983;286:1395–6. - PMC - PubMed
    1. Demir AM, Kuloglu Z, Berberoglu M, et al. Euprolactinemic galactorrhea secondary to domperidone treatment. J Pediatr Endocrinol Metab. 2015;28:955–6. - PubMed
    1. De S, Taylor CM. Domperidone toxicity in an infant on maintenance haemodialysis. Pediatr Nephrol. 2007;22:161–2. - PubMed
    1. Livingstone V, Blaga Stancheva L, Stringer J. The effect of withdrawing domperidone on formula supplementation. Breastfeed Med. 2007;2:178–Abstract 3. doi: 10.1089/bfm.2007.9985. - DOI
    1. Campbell-Yeo ML, Allen AC, Joseph KS, et al. Effect of domperidone on the composition of preterm human breast milk. Pediatrics. 2010;125:e107–14. - PubMed
    1. Wagner CL, Murphy PK, Haase B, et al. Domperidone in the treatment of low milk supply in mothers of critically ill neonates. Breastfeed Med 2011;6 (Suppl 1):S-21. Abstract. doi:10.1089/bfm.2011.9985 - DOI
    1. Inam I, Navinés AB, Shahid A. A comparison of efficacy of domperidone and placebo among postnatal women with inadequate breast milk production. Pak J Med Health Sci. 2013;7:314–6.
    1. Haase B, Taylor S, Morella K, et al. Domperidone for treatment of low milk supply in mothers of hospitalized premature infants: A multidisciplinary development of safe prescribing guidelines and a retrospective chart review (2010-2014) of maternal response to treatment. Breastfeed Med. 2016;11:A22–Abstract P11. doi: 10.1089/bfm.2016.28999.abstracts. - DOI
    1. Haase B, Taylor SN, Mauldin J, et al. Domperidone for treatment of low milk supply in breast pump-dependent mothers of hospitalized premature infants: A clinical protocol. J Hum Lact. 2016;32:373–81. - PubMed
    1. Rai R, Mishra N, Singh DK. Effect of domperidone in 2nd week postpartum on milk output in mothers of preterm infants. Indian J Pediatr 2016;83:894-5. Letter. PMID: 27109392 - PubMed
    1. Fazilla TE, Tjipta GD, Ali M, et al. Domperidone and maternal milk volume in mothers of premature newborns. Paediatr Indones. 2017;57:18–22. doi: 10.14238/pi57.1.2017.17-22. - DOI
    1. Asztalos EV, Kiss A, da Silva OP, et al. Pregnancy gestation at delivery and breast milk production: A secondary analysis from the EMPOWER trial. Matern Health Neonatol Perinatol. 2018;4:21. - PMC - PubMed
    1. Asztalos EV, Kiss A, da Silva OP, et al. Evaluating the effect of a 14-day course of domperidone on breast milk production: A per-protocol analysis from the EMPOWER trial. Breastfeed Med. 2019;14:102–7. - PubMed
    1. Asztalos EV, Kiss A, da Silva OP, et al. Role of days postdelivery on breast milk production: A secondary analysis from the Empower trial. Int Breastfeed J. 2019;14:21. - PMC - PubMed
    1. Grzeskowiak LE, Amir LH, Smithers LG. Longer-term breastfeeding outcomes associated with domperidone use for lactation differs according to maternal weight. Eur J Clin Pharmacol. 2018;74:1071–5. - PubMed
    1. Wada Y, Suyama F, Sasaki A, et al. Effects of domperidone in increasing milk production in mothers with insufficient lactation for infants in the neonatal intensive care unit. Breastfeed Med. 2019;14:744–7. - PubMed
    1. Maged AM, Hassanin ME, Kamal WM, et al. Effect of low-level laser therapy versus electroacupuncture on postnatal scanty milk secretion: A randomized controlled trial. Am J Perinatol. 2020;37:1243–9. - PubMed
    1. Khorana M, Wongsin P, Torbunsupachai R, et al. Effect of domperidone on breast milk production in mothers of sick neonates: A randomized, double-blinded, placebo-controlled trial. Breastfeed Med. 2021;16:245–50. - PubMed
    1. LeCain M, Fraterrigo G, Drake WM. Induced lactation in a mother through surrogacy with complete androgen insensitivity syndrome (CAIS). J Hum Lact. 2020;36:791–4. - PubMed

 MISSION ACCOMPLISHED:    13 November 2021 -  0mg Pristiq      

Woohoo!!!  Finally off Pristiq   

ADs since ~1992:  25+ years - 1 unknown, Prozac (muscle weakness), Zoloft; citalopram (pooped out) CTed (very sick for 2.5 wks a few months after); Pristiq:  50mg 2012, 100mg beg 2013 (Serotonin Toxicity)  Tapering from Oct 2015 - 13 Nov 2021   LAST DOSE 0.0025mg

My full tapering program     My Intro (goes to my tapering graph)    My website

PLEASE NOTE:  I am not a medical professional.  I provide information and make suggestions.  I do not provide tapering advice via PM.  Please post questions in your Introduction topic.  Please do not tag me for any reason.  I am an unpaid volunteer and assist members if I am able to and when I have the time.  Thank you for your understanding.

Mid Nov 2021 changed to low carb diet due to diabetes & cholesterol.  Lost 1/16 body weight, BP has reduced a lot. 

Links to my exercises and weights.  I also do 3 x 5.5 min with HIIT on exercise bike with 20 secs/min as fast as I can cycle.

Link to comment
Share on other sites

  • Altostrata changed the title to Drugs and Lactation Database, 2021 Domperidone Review

  • Create New...

Important Information

Terms of Use Privacy Policy